Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
التفاصيل البيبلوغرافية
العنوان:
Supplementary Table 2 from Combination Nivolumab, CD137 Agonism, and Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes for Patients with Metastatic Melanoma
American Association for Cancer Research (AACR), 2023.
سنة النشر:
2023
الوصف:
Supplementary Table 2 contains the Representativeness Table which demonstrates how this study fits into the larger patient population for metastatic melanoma.